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Table 1
Patient Characteristics
Patient characteristics N¼5
Age 7.5 years (3-11)
Sex (M: F) 4:1
Phase of therapy Induction (week 3-5):4
Delayed Intensiﬁcation: 1
Presenting features Fever: 100%
Seizures: 80%
Altered sensorium: 20%
Preceding focus (100%) Pneumonia: 4
ASOM: 1
Neutropenia (100%) Median duration 16 days (14-23)
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ROLE OF CARDIAC BIOMARKERS IN DETECTION OF MYOCARDIAL
DAMAGE IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ANTHRACYCLINES
Sunil Kumar Singh 1, Rimjhim Sonowal 1, Vikas Agrawal 2, Vineeta
Gupta 1. 1Department of Pediatrics, Institute of Medical Sciences, Banaras
Hindu University, Varanasi, India; 2Department of Cardiology, Institute of
Medical Sciences, Banaras Hindu University, Varanasi, India
Objective: Anthracyclines exposure during treatment of childhood malig-
nancies poses a high risk for development of late cardiotoxicity. Car-
diotoxicity is usually diagnosed when patient is symptomatic with
progressive cardiac dysfunction. Early detection is important to institute
early therapeutic interventions to improve outcome. Aim of present study
was to evaluate cardiac troponin T (cTnT), N-terminal probrain natriuretic
peptide (NT-pro BNP) and creatinine kinase MB isoenzyme (CK-MB) and
echocardiography in the detection of cardiac abnormalities in asymptom-
atic children treated for hematological malignancies with anthracyclines.
Methods: Serum levels of cTnT, NT-pro BNP and CK-MB were measured in
40 survivors (26 males and 14 females) of hematological malignancies (20
high risk acute lymphoblastic leukemia and 20 Hodgkin lymphoma pa-
tients). All patients had received >200 mg/m2 cumulative dose of
anthracyclines and were more than 2 years post chemotherapy. 30 healthy
children were taken as controls. Echocardiography using M-mode and
Doppler measurements were performed on same day as blood in-
vestigations. Study was approved by Institute Ethics committee.
Results: Serum levels of NT-proBNP were signiﬁcantly higher in patients
compared to controls (48.69 ± 20.36 vs 5.08 ± 3.74 pg/ml; p value <0.01). 6
of the patients had left ventricular (LV) dysfunction with mean NT-proBNP
levels of 67.29 ± 22.73 pg/ml which was signiﬁcantly higher than patients
who had normal LV function (mean NT-proBNP levels of 36.19 ± 21.93 pg/
ml. Levels correlated inversely with fractional shortening and ejection
fraction and positively with the cumulative dose of anthracyclines. No
difference was observed between males and females. Serum levels of cTnT
and CK-MB were higher in the patients but they were not statistically
signiﬁcant.
Conclusions: NT-pro-BNP is a sensitive test and correlates with cardiac
function It can be used as a useful biomarker for early detection of
anthracycline cardiotoxicity.TM_SC-1_V1.5
EVALUATION OF SERUM PROCALCITONIN, SERUM INTERLEUKIN-6 AND
INTERLEUKIN-8 TO PREDICT RISK GROUPS IN CHILDREN WITH FEBRILE
NEUTROPENIA AND CANCER
Nuthan Kumar, Fellow 1, Supriya Suresh Gujjar 1, Arathi Srinivasan, Junior
Consultant 2, Padma Keerthiga, Senior Consultant 3, Julius Xavier Scott,
Senior Consultant 4. 1Department of Pediatric Hematology and Oncology,
Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India;
2Department of Pediatric Hematology and Oncology, Kanchi Kamakoti
Childs Trust Hospital, Chennai, Tamil Nadu, India; 3Department of
Biochemistry, Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu,
India; 4Department of Pediatric Hematology and Oncology, Kanchi
Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, IndiaBackground: Early diagnosis of sepsis in childrenwith febrile neutropenia
remains difﬁcult due to non-speciﬁc clinical and laboratory signs of
infection. There is a need to assess the utility of inﬂammatory markers in
clinical risk assessment for their ability to discriminate between low-risk
and high-risk neutropenic patients since presently there is an insufﬁcient
data to recommend their routine use.
Study design andmethodology: This is a prospective study of children on
therapy admitted with febrile neutropenia between 2015-2016 and
sampled for markers at admission. The febrile neutropenia episodes were
categorized into two groups - Group I:no focus of infection and Group
II:clinically/microbiologically documented infection. Statistical analysis for
comparison were performed using z-test and Receiver operating curves at
various cut-off levels.
Results: A total of 46 episodes of febrile neutropenia were analysed. 76%
were categorized as group I and 24% as group II. The mean value of PCT in
group II was higher (28.07 ng/ml) as compared to group I (1.03ng/ml)
though there was no signiﬁcant statistical difference. At a cut off level of 2
ng/ml for PCT, sensitivity of 63%, speciﬁcity of 91%, PPV of 70%, NPV of 88%
were observed. There was no signiﬁcant difference in the IL-6 and IL-8
levels between both the groups. But at an optimal cut off value of 50 pg/ml,
IL-6 had a NPV of 80% and at a cut off level of 130 pg/ml, IL-8 had a NPV of
73%, however with low sensitivity and speciﬁcity.
Conclusion: IL-6, IL-8 and PCT can be utilized to deﬁne a group of patients
with a low risk of sepsis in view of their favorable NPV. The utility of these
biomarkers together can facilitate early discharge from the hospital, and
the use of oral antimicrobial therapy in turn reducing the cost of therapy
especially in a developing country.
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VITAMIN D STATUS IN NEWLY DIAGNOSED PEDIATRIC ONCOLOGY
PATIENTS AT A TERTIARY CARE HOSPITAL
Purvi Kadakia, Maaz Ahmed, Dhwani Shah, Girish Rajadhyaksha. Department
of Medical Oncology, TNMC & B.Y.L Nair Hospital, India
Introduction: Vitamin D or 25-Hydroxycholecalciferol, an important
immunomodulator, is commonly found to be deﬁcient in healthy young
children as well as in adolescent age group with prevalence of about 50 to
90 % in India. Vitamin D has important anticancer effects such as poten-
tiating apoptosis, prevents proliferation and inhibits angiogenesis. There is
paucity of data on status of vitamin D levels in Pediatric oncology patients
and recently its deﬁciency has been suggested to be associated with can-
cer. Our aim was to study status of vitamin D level in newly diagnosed
Pediatric Oncology patients at a tertiary centre.
Material and Methods: The study included all the newly diagnosed Pe-
diatric oncology cases (solid and hematological neoplasm) between the
age group of 1 to 18 years at a tertiary care centre in a metropolitan city in
India over a period of 12 months from June 2015 to July 2016. The vitamin
D level was done at the time of diagnosis after informed consent from
parents and assent from children above seven years was obtained. Two ml
of fasting blood was collected in a plain bulb which was analysed for 25-
hydroxy cholecalceferol by ELISA method. The age, sex, diagnosis and
vitamin D level at time of diagnosis was recorded in case record form. The
vitamin D level was stratiﬁed as deﬁciency, insufﬁciency, sufﬁciency and
toxicity level as per classiﬁcation by US endocrine society. The data anal-
ysis was done with SSPS software.
Results: Forty one patients were enrolled in the study of which 70.7% were
males. Ten (24.4%) were in the age group of 1 to 5 years, 27 (65.9%)
belonged to 5-14 years and only 4 belonged to 14- 18 years. The study
revealed 32 (78%) children had vitamin D level below 20 ng/dl that is
deﬁcient, 5 (12.19%) patients were between 21- 29 ng/ml indicating
insufﬁciency and only 4 (9.75%) were sufﬁcient which was vitamin D level
more than 30ng/dl. Among 32 deﬁcient patients, nine (28 .4%) were in the
age group of 1 to 5 years, 19 (59.3%) belonged to 5-14 years and 71.1% were
males. Among the subgroup of sufﬁcient vitamin D level, all were males.
Pre B cell acute lymphocyte leukemia (28%) followed by Hodgkin's lym-
phoma (12%) were common malignancies among deﬁcient subgroup.
Conclusion: There is a high prevalence of Vitamin D deﬁciency and
insufﬁciency (90.19%) among Pediatric oncology patients at the time of
diagnosis as described in our cohort. The impact of vitamin D screening
